Oct 1 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab, Takeda Pharmaceuticals (4502.T), opens new tab and Astex Pharmaceuticals are coming together to share proprietary data for training an ...

Among the horde of new devices Amazon unveiled during its New York City event on Tuesday are two new Echo speakers: a higher-end Echo Dot called the Echo Dot Max and a next-generation Echo Studio with ...

Results demonstrate that DIAG723, the Company's lead clustering antibody, can prevent PAH, offering the potential as a first-in-class PAH treatment PAH is a progressive and life-threatening disorder ...

EXCLUSIVE: As AI continues to infiltrate the entertainment industry, Particle6 founder and CEO Eline Van Der Velden is taking it one step further with the launch of Xicoia, an AI talent studio ...

Brandy Byrd Chapman, a data center security expert for Ameristar Perimeter Security, has delivered a consistent message to clients during her nine years in the industry. “Security should not be an ...

Alibaba shares surge 9.7% to four-year high on AI announcements Company partners with Nvidia, plans new data centers globally Unveils Qwen3-Max AI model with over one trillion parameters BEIJING, Sept ...

From Machines To A "Digital Foundry" Velo3D doesn't see itself as a machine seller — it sees itself as the AWS (Amazon Web Services) of manufacturing. "Customers don't just need machines, they need ...

Visual Studio Code now has a new auto AI model selector that favors Claude 4 over GPT-5. Visual Studio Code now has a new auto AI model selector that favors Claude 4 over GPT-5. is a senior editor and ...

Elon Musk’s A.I. firm is scaling back on “generalist A.I. tutors.” Allison Robbert/POOL/AFP via Getty Images Data annotation may not be the most glamorous job in Silicon Valley, but it’s indispensable ...

Not to be confused with Chinese AI lab Moonshot's recently released, powerful, open source model Kimi K2, another new open source large language model (LLM) called "K2 Think" debuted today, and it's ...

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – ...